On Demand: Evolution of Flow Cytometry in Infectious Disease Research
In many cases, the human body has found ways in which to overcome many of the deleterious effects of infectious disease pathogens.
The systems by which the human body has the ability to fight most of these pathogens are being explored. The development of many vaccines and pathways, in the fight against many pathogen acquired diseases, has been progressed due to knowledge of these systems.
This panel discussion focuses on the use of advanced flow cytometry, within four pathogenesis aspects, of the human body response to infectious diseases: Infection and Replication, Antibody Response, Post Infection and Protective Immunity.
Hear how our panelists study the various infection stages and the directions of their studies of infectious diseases.
Key webinar discussion topics include:
- Antibody Discovery & Screening
- Antibody neutralization assays
- Host Immune Response: immune-based assays for T cell activation, exhaustion, NK and T cell mediated cell killing
- Functional antibody screens: phagocytosis, antibody-dependent internalization
- Vaccine development: epitope screening
- Target Identification with cell-based target screening, display-based library screens, phage, yeast and VLP
- Antibody titers and cell health
Colby Souders, Ph.D.
Chief Scientific Officer
Colby Souders holds a PhD in Cell and Molecular Biology from Texas A&M and prior to Abveris was part of MassBiologics of the University of Massachusetts Medical School and Kanyos Bio (now Anokion). At MassBiologics, he worked to advance monoclonal antibodies for the prevention, treatment or diagnosis of various infectious and endogenous diseases, as well as develop related platform technologies to advance and expand the MassBiologics pipeline.
Later, he joined the Kanyos Bio Protein Engineering team to develop therapeutics based on a novel antigen-specific immune tolerance platform. With the successful completion of multiple antibody discovery, affinity maturation and protein engineering campaigns that helped advance lead molecules to clinical trials, Colby joined Abveris in August of 2018. As Chief Scientific Officer, he helps guide the team to usher in a new generation of antibody discovery tools and build a premium discovery engine with industry-leading timelines.
Tabb Sullivan, Ph.D.
Technical and Applications Lead Scientist
Tabb Sullivan is Integral Molecular’s technical and applications lead scientist for the Membrane Proteome Array (MPA). Tabb develops new technology to use with the MPA and maximize throughput for MPA screens.
Tabb has recently been assisting the virology team in developing the SARS-CoV-2 RVPs and associated cell lines and protocols.